Literature DB >> 12581513

HIV-mediated gammadelta T cell depletion is specific for Vgamma2+ cells expressing the Jgamma1.2 segment.

Patrick J Enders1, Cheng Yin, Federico Martini, Peter S Evans, Nadia Propp, Fabrizio Poccia, C David Pauza.   

Abstract

Circulating Vgamma2/Vdelta2(+) T cells, normally constituting 3-6% of all CD3(+) T cells in blood, are severely depleted after HIV infection. The mechanism(s) for Vgamma2/Vdelta2(+) T cell depletion are unknown, partly because these cells are CD4(-) and resistant to HIV infection. To determine whether this cell depletion was general for all Vgamma2(+) cells or specific for an individual subset, we analyzed the Vgamma2 repertoire and found consistent differences between HIV(+) and uninfected control samples. The change in Vgamma2 repertoire was the result of preferentially depleting only those Vgamma2 cells that express the Jgamma1.2 segment. The specific loss of Vgamma2-Jgamma1.2(+) cells was polyclonal, as the Vgamma subset retained normal diversity even after HIV infection, and loss occurred without significant changes in the paired chain (Vdelta2) repertoire, or in the alternate Vdelta1 chain repertoire. Specific depletion of Vgamma2-Jgamma1.2/Vdelta2 T cells is the first evidence of a common, T cell receptor-dependent cell loss in HIV disease and it provides a clear example of bystander cell depletion. Vgamma2-Jgamma1.2/Vdelta2 T cells mediate potent responses to microbial pathogens including HIV, and loss of this subset is an important aspect of AIDS pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12581513     DOI: 10.1089/08892220360473934

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  31 in total

1.  Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens.

Authors:  Andrew M Hebbeler; Cristiana Cairo; Jean Saville Cummings; C David Pauza
Journal:  Cancer Immunol Immunother       Date:  2006-11-28       Impact factor: 6.968

2.  Innate-like gammadelta T cell responses to mycobacterium Bacille Calmette-Guerin using the public V gamma 2 repertoire in Macaca fascicularis.

Authors:  Cristiana Cairo; Andrew M Hebbeler; Nadia Propp; Joseph L Bryant; Vittorio Colizzi; C David Pauza
Journal:  Tuberculosis (Edinb)       Date:  2007-02-09       Impact factor: 3.131

3.  Interleukin-18 activates Vγ9Vδ2+ T cells from HIV-positive individuals: recovering the response to phosphoantigen.

Authors:  Alanna S Murday; Suchita Chaudhry; C David Pauza
Journal:  Immunology       Date:  2017-05-24       Impact factor: 7.397

4.  Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy.

Authors:  Michael A Poles; Shady Barsoum; Wenjie Yu; Jian Yu; Patricia Sun; Jeanine Daly; Tian He; Saurabh Mehandru; Andrew Talal; Martin Markowitz; Arlene Hurley; David Ho; Linqi Zhang
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells.

Authors:  David J Riedel; Mohammad M Sajadi; Cheryl L Armstrong; Jean-Saville Cummings; Cristiana Cairo; Robert R Redfield; C David Pauza
Journal:  AIDS       Date:  2009-09-24       Impact factor: 4.177

Review 6.  Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: mechanisms, impacts and therapeutic implications.

Authors:  Haishan Li; Suchita Chaudhry; Suchita Chaudry; Bhawna Poonia; Yiming Shao; C David Pauza
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

7.  The γδ T-cell receptor repertoire is reconstituted in HIV patients after prolonged antiretroviral therapy.

Authors:  Suchita Chaudhry; Cristiana Cairo; Vanessa Venturi; C David Pauza
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

8.  Gammadelta T cell immune manipulation during chronic phase of simian-human immunodeficiency virus infection [corrected] confers immunological benefits.

Authors:  Zahida Ali; Lin Yan; Nicholas Plagman; Armin Reichenberg; Martin Hintz; Hassan Jomaa; Francois Villinger; Zheng W Chen
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

Review 9.  Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells.

Authors:  Elizabeth M Urban; Andrei I Chapoval; C David Pauza
Journal:  Clin Dev Immunol       Date:  2010-04-13

Review 10.  Role of the Fas/FasL pathway in HIV or SIV disease.

Authors:  Bhawna Poonia; C David Pauza; Maria S Salvato
Journal:  Retrovirology       Date:  2009-10-15       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.